Study Evaluating Etanercept for the Treatment of Active, Severe, and Advanced Axial Ankylosing Spondylitis

• Status: Completed
• Trial end date: 2009-05-01
• Target enrollment: 0
• Participant gender: All

Summary

Evaluation of the efficacy and safety of etanercept (Enbrel) in patients with active, severe and advanced ankylosing spondylitis.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Wyeth is now a wholly owned subsidiary of Pfizer
• Treatments: Etanercept

Criteria

Inclusion criteria

• Active and severe ankylosing spondylitis

• Ankylosing spondylitis refractory to standard anti-rheumatic treatment

• Between 18 and 70 years of age

Exclusion criteria

• Prior exposure to any TNF-inhibitor, including etanercept

• DMARDs (other than hydroxychloroquine, methotrexate and sulphasalazine) within 4 weeks of study drug initiation

• Dose of NSAIDs changed within two weeks of study drug initiation